11Apr

[Personal View] Challenges of modifying disease progression in prediagnostic Parkinson’s disease

Neurodegeneration in Parkinson's disease starts years before a clinical diagnosis can be reliably made. The prediagnostic phase of the disease offers a window of opportunity in which disease-modifying therapies—ie, those aimed at delaying or preventing the progression to overt disease and its many complications—could be most beneficial, but no such therapies are available at present. The unravelling of the mechanisms of neurodegeneration from the earliest stages, however, could lead to the development of new interventions whose therapeutic potential will need to be assessed in adequately designed clinical trials.

Ander nieuws

20May

[Review] CSF and blood biomarkers for Parkinson’s disease

In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urg...

naar nieuwsitem

20May

[Comment] A new step towards targeting tau

Progressive supranuclear palsy is a rare neurodegenerative disease characterised by an axial parkins...

naar nieuwsitem

22Apr

Parkinson’s disease patient: ‘I can walk… it’s really helped me’

Parkinson's disease patient Gail Jardine can walk more freely after having a spinal implant fit...

naar nieuwsitem